Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I
- PMID: 31658729
- PMCID: PMC6958392
- DOI: 10.3390/ph12040152
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Review of Classical and New Compounds: Part-I
Abstract
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed.
Keywords: diabetes mellitus; glucose-lowering agents; metabolic syndrome; phytotherapy; sugar-lowering oils.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- Porth C.M. Essentials of Pathophysiology: Concepts of Altered Health States. 3rd ed. Volume 3. Wolters Kluwer; Alphen aan den Rijn, The Netherlands: Oct 15, 2010. ISBN-10 1582557241; ISBN-13 978-1582557243.
-
- Vieira R., Souto S.B., Sanchez-Lopez E., Machado A.L., Severino P., Jose S., Santini A., Silva A.M., Fortuna A., Garcia M.L., et al. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II. J. Clin. Med. 2019;8:1332. doi: 10.3390/jcm8091332. - DOI - PMC - PubMed
